Literature DB >> 3129007

(+)-sulpiride antagonises the renal effects of gamma-L-glutamyl-L-dopa in man.

T M MacDonald1, R F Jeffrey, S Freestone, M R Lee.   

Abstract

1. gamma-L-glutamyl-L-dopa (gludopa) was given by intravenous infusion to six healthy salt-replete men on two occasions, with and without pretreatment with (+)-sulpiride. 2. Gludopa increased sodium excretion, glomerular filtration rate and effective renal plasma flow whilst decreasing plasma renin activity. 3. (+)-sulpiride had no significant effect on baseline natriuresis, renal haemodynamics or plasma renin activity, but significantly attenuated the rise in sodium excretion, glomerular filtration rate and effective renal plasma flow produced by gludopa. 4. (+)-sulpiride abolished the acute fall in plasma renin activity seen with gludopa. 5. (+)-sulpiride raised serum prolactin concentration but did not affect the ris in urine dopamine excretion rate caused by gludopa. 6. Gludopa exerts its renal effects by stimulating specific dopamine receptors which are principally of the DA1 subtype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129007      PMCID: PMC1386475          DOI: 10.1111/j.1365-2125.1988.tb03292.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

2.  Renal extraction of para-aminohippurate and creatinine measured by continuous in vivo sampling of arterial and renal-vein blood.

Authors:  R B HARVEY; A J BROTHERS
Journal:  Ann N Y Acad Sci       Date:  1962-10-31       Impact factor: 5.691

3.  Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous gamma-L-glutamyl-L-dopa.

Authors:  D P Worth; J N Harvey; J Brown; A Worral; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  [Hypertensive episodes initiated by sulpiride (Dogmatil)].

Authors:  P Corvol; F Bisseliches; J M Alexandre; C Bohuon; J P Heurtault; J Ménard; P Tcherdakoff; J C Vaysse; P Milliez
Journal:  Ann Med Interne (Paris)       Date:  1973 Aug-Sep

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  The purification of human prolactin from frozen pituitary glands.

Authors:  P Hwang; M Robertson; H Guyda; H Friesen
Journal:  J Clin Endocrinol Metab       Date:  1973-06       Impact factor: 5.958

7.  A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man.

Authors:  R Fraser; S Guest; J Young
Journal:  Clin Sci Mol Med       Date:  1973-09

8.  Application of Heyrovsky's inulin method to automatic analysis.

Authors:  J K Dawborn
Journal:  Clin Chim Acta       Date:  1965-07       Impact factor: 3.786

9.  Metoclopramide decreases renal plasma flow.

Authors:  R Israel; V O'Mara; B Austin; A Bellucci; B R Meyer
Journal:  Clin Pharmacol Ther       Date:  1986-03       Impact factor: 6.875

10.  The effect of carbidopa and indomethacin on the renal response to gamma-L-glutamyl-L-dopa in normal man.

Authors:  R F Jeffrey; T M MacDonald; K Marwick; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

View more
  10 in total

1.  Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension.

Authors:  L D Asico; C Ladines; S Fuchs; D Accili; R M Carey; C Semeraro; F Pocchiari; R A Felder; G M Eisner; P A Jose
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

2.  The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man.

Authors:  D Worth; J Harvey; J Brown; M Lee
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Metoclopramide, domperidone and dopamine in man: actions and interactions.

Authors:  T M MacDonald
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.

Authors:  T M MacDonald; K Craig; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

5.  The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure.

Authors:  Y A Boateng; H E Barber; T M MacDonald; J C Petrie; M R Lee; P H Whiting
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

6.  Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers.

Authors:  Y A Boateng; H E Barber; T M MacDonald; J C Petrie; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

7.  The renal handling of dopamine originating from L-dopa and gamma-glutamyl-L-dopa.

Authors:  M Pestana; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

8.  The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride.

Authors:  S Freestone; T M MacDonald; R F Jeffrey; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

9.  The renal and haemodynamic effects of a 10 h infusion of glutamyl-L-dopa in normal man.

Authors:  T M MacDonald; R F Jeffrey; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

10.  Association of Dopamine D1 and D3 Receptor Gene Polymorphisms with Essential Hypertension in 3 Ethnic Groups in China.

Authors:  Hongju Yang; Lianmei Zhong; Song Bai; YiLong Dong; Yanmei Wang; Qian Li; Qiuping Yang; Dejun Jiang; Hongyan Bi; Chunjie Xiao; Bingron Zheng
Journal:  Med Sci Monit Basic Res       Date:  2017-06-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.